Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer

Abstract

The 3p21.3 tumour suppressor gene (TSG) RASSF1A is inactivated predominantly by promoter methylation and rarely by somatic mutations. Recently we demonstrated that epigenetic inactivation of RASSF1A is frequent in both clear cell and papillary adult renal cell carcinomas (even though 3p21.3 allele loss is rare in papillary tumours). Wilms' tumour is the most common childhood kidney tumour, but relatively little is known about its molecular pathogenesis. Thus TSGs such as WT1, p16(CDKN2a) and p53 are inactivated in only a minority of cases. In view of the involvement of RASSF1A in adult renal cancers we investigated RASSF1A as a candidate Wilms' TSG. We detected RASSF1A hypermethylation in 21 of 39 (54%) primary Wilms' tumours. 3p21.3 allele loss was not detected in nine informative Wilms' tumours (five with RASSF1A methylation). In contrast to RASSF1A, only a minority (10.3%) of Wilms' tumours demonstrated p16 promoter methylation. As chromosome 3p allele loss is frequent in colorectal cancer, we proceeded to investigate RASSF1A promoter methylation in colorectal cancer and detected RASSF1A methylation in 80% (4/5) colorectal cancer cell lines and 45% (13/29) primary colorectal cancers. There was no correlation between RASSF1A and p16 methylation in colorectal cancer. We have demonstrated that RASSF1A inactivation is the most frequent genetic or epigenetic event yet reported in Wilms' tumourigenesis and that allelotyping studies may fail to identify regions containing important TSGs.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 3
Figure 2

Similar content being viewed by others

References

  • Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER, Latif F . 2001 Oncogene 20: 1509–1518

  • Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP . 1998 Cancer Res. 58: 5489–5494

  • Arcellana-Panlilio MY, Egeler RM, Ujack E, Pinto A, Demetrick DJ, Robbins SM, Coppes MJ . 2000 Gene Chromosome Cancer 29: 63–69

  • Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HP, Voutilainen R, Dahia P, Eng C, Maher ER, Latif F . 2001 Oncogene 20: 7573–7577

  • Bardeesy N, Falkoff D, Petruzzi MJ, Nowak N, Zabel B, Adam M, Aguiar MC, Grundy P, Shows T, Pelletier J . 1994 Nat. Genet. 7: 91–97

  • Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP . 1998 Adv. Cancer Res. 72: 141–196

  • Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Gao B, Randle D, Virmani A, Bader S, Sekido Y, Latif F, Fong K, Gazdar AF, Lerman MI, White M, Minna JD . 2001 J. Natl. Cancer Inst. 93: 691–699

  • Costello JF, Plass C . 2001 J. Med. Genet. 38: 285–303

  • Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP . 1998 Nat. Med. 4: 1276–1280

  • Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP . 2000 Nat. Genet. 25: 315–319

  • Davies R, Moore A, Schedl A, Bratt E, Miyahawa K, Ladomery M, Miles C, Menke A, van Heyningen V, Hastie N . 1999 Cancer Res. 59: Suppl S1747–S1750 discussion S1751

  • Hao X, Willis IE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TR . 2000 Cancer Res. 60: 18–21

  • Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 9821–9826

  • Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM . 1994 Proc. Natl. Acad. Sci. USA 91: 9700–9704

  • Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB . 1998 Proc. Natl. Acad. Sci. USA 95: 6870–6875

  • Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB . 1996 Proc. Natl. Acad. Sci. USA 93: 11757–11762

  • Jones PA . 1999 Trends Genet. 15: 34–37

  • Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R . 1997 Cancer Res. 57: 808–811

  • Lee SB, Haber DA . 2001 Exp. Cell Res. 264: 74–99

  • Lerman MI, Minna JD . 2000 Cancer Res. 60: 6116–6133

  • Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA, Licht JD, Atweh GF . 1995 Oncogene 11: 743–750

  • Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F, Maher ER . 2001 Cancer Res. 61: 7277–7281

  • Moulton T, Crenshaw T, Hao Y, Moosikasuwan J, Lin N, Dembitzer F, Hensle T, Weiss L, McMorrow L, Loew T, Kraus W, Gerald W, Tycko B . 1994 Nat. Genet. 7: 440–447

  • Okamoto K, Morison IM, Taniguchi T, Reeve AE . 1997 Proc. Natl. Acad. Sci. USA 94: 5367–5371

  • Pao MM, Tsutsumi M, Liang G, Uzvolgyi E, Gonzales FA, Jones PA . 2001 Hum. Mol. Genet. 10: 903–910

  • Richards FM, Schofield PN, Fleming S, Maher ER . 1996 Hum. Mol. Genet. 5: 639–644

  • Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL, Feinberg AP . 1994 Nat. Genet. 7: 433–439

  • Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M, Clark SJ . 1997 Cancer Res. 57: 2229–2237

  • Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JK, Markowitz SD, Leach FS, Kinzler KW, Vogelstein B . 1996 Cancer Res. 56: 2936–2939

  • Toyota M, Ohe-Toyota M, Ahuja N, Issa JPJ . 2000 Proc. Natl. Acad. Sci. USA 97: 710–715

  • Tycko B . 2000 J. Clin. Invest. 105: 401–407

  • van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, Arends JW, van den Brandt PA, de Goeij AF, Herman JG . 2002 Oncogene 21: 3792–3795

  • Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ . 2000 J. Biol. Chem. 275: 35669–35672

  • Waber PG, Chen J, Nisen PD . 1993 Cancer 72: 3732–3738

Download references

Acknowledgements

We thank Carol Hardy for 11p LOH analysis and Dr FM Richards, Dr J Kingdom and Dr L Wong for human foetal RNA. We also thank the Association for International Cancer Research, Cancer Research Campaign and SPARKS for financial support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eamonn R Maher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wagner, K., Cooper, W., Grundy, R. et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 21, 7277–7282 (2002). https://doi.org/10.1038/sj.onc.1205922

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205922

Keywords

This article is cited by

Search

Quick links